

DAFTAR PUSTAKA

1. Dai X, Xiang L, Li T, Bai Z. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. *Journal of Cancer*. 2016 June 23;7(10):1281-1294.
2. Alteri R, Bertaut T, Brinton LA, Fedewa S, Freedman RA, Gansler T, et al. American Cancer Society. *Breast Cancer Facts & Figures 2015-2016*. Georgia : American Cancer Society; 2015;4:4-7.
3. Panigoro S, Hernowo BS, Purwanto H, Handojo, Haryono SJ, Arif W, et al. (Komite Penanggulangan Kanker Nasional Kementerian Kesehatan RI). *Pedoman Nasional Pelayanan Kanker Payudara*. Jakarta : Kementerian Kesehatan RI ; 2015.
4. Kementerian Kesehatan RI. *InfoDatin Bulan Peduli Kanker Payudara 2016*. Jakarta : Pusat Data dan Informasi Kementerian Kesehatan RI; 2016.
5. Mitchell N, Kumar V, Abbas K, *et al.* Tania I, editors. *Buku Saku Dasar Patologis*. 7th ed. Jakarta: EGC; 2008; p. 169–205.
6. Roy, Rohini. Chun, Jarin. Powell, SN. BRCA 1 and BRCA 2 : different roles in common pathway of genome protection. *Nat Rev Cancer*. 2016 August 03:12(1).68-78
7. Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, et al. Cell Cycle Control of BRCA2. *Cancer research*. 1996 October 15;56: 4590-4.
8. Andres JL, Fan S, Turkel GJ, Wang JA, Twu NF, Yuan RQ, *et al.* Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents. *Oncogene*. 1997 November 27; 16: 2229-41.
9. Wulandari, Catharina Endah. Hereditary Breast Ovarian Cancer (HBOC) Syndrome. *CDK-222*. 2014; 41(11).
10. Reddy K.B. Triple-Negative Breast Cancers: An Updated Review On Treatment Options. *Medical Current Oncology*. 2011; 18 (4).
11. Vissac C, De Latour MP, Communal Y, Bignon YJ, Bernard-Gallon DJ. Expression of BRCA1 and BRCA2 in different tumor cell lines with various growth status. *Clinica Chimica Acta Elsevier*. 2002;320:101– 10
12. Akslen, LA. Molecular Classification of Breast Cancer. Centre for Cancer Biomarkers CCBIO. Department of Clinical Medicine, Section for Pathology. University of Bergen - Haukeland University Hospital ; May 2015.
13. Yersal O, Barutca S. Biological Subtypes Breast Cancer : Prognostic and Therapeutic Implications. *World Journal Clinical Oncology*. 2014 August 10; 5(3): 412-424.
14. Holliday DL, Speirs V. Choosing The Right Cell Line For Breast Cancer Research. *Breast Cancer Research*. 2011, 13:1;1-5.
15. Diessner J, Wischnewsky M, Blettner M, Hausler S, Janni W, Kreienberg R, et al. Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study. *PLoS ONE* 11(12). December 19, 2016;1-15.

16. Dixon, J.M. Endocrine Resistance in Breast Cancer. *New Journal of Science*. 2014 September 17.2014:1-28
17. American Type Culture Collection Breast Cancer Panel. *Breast Cancer Resources Book*. ATCC. 2015
18. Manavathi B, Dey O, Gajulapalli VNR, Bhatia RS, Bugide S, Kumar R. Derailed Estrogen Signaling and Breast Cancer: An Authentic Couple. *Endocrine Reviews*. December 2012; 33(6): 1-31.
19. Ha SM, Chae HY, Cha JH, Kim HH, Shin HJ, Choi WJ. Association of *BRCA* Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With *BRCA 1* and *BRCA 2* Mutations. *AJR*. October 2017;297.
20. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, *et al*. Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery. *PLoS ONE*. July 2009; 4(7).
21. Halim D, Murti H, Sandra F, Boediono A, Djuwantono T, Setiawan B. *Stem Cell– Dasar Teori dan Aplikasi Klinis*. Jakarta:Erlangga;2010.p.4-125
22. Dominici M, Blanc KL, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006; 8(4):315-7.
23. Klopp AH, Gupta A, Spaeth E, Andreeff BM, Marini FB. Concise Review: Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth?. *Stem Cells*. 2011;29:11–9
24. Suter, Rachel. Marcum JA. *The Molecular Genetics Of Breast Cancer And Targeted Therapy*. *Biologics : Targets and Therapy*. 2007;1(3).241-258
25. Adelipour M, Babaei F, Mirzababaei M, Allameh A. Correlation of micro vessel density and c-Myc Expression in breast tumor of mice following mesenchymal stem cell therapy. *Elsevier Tissue and Cells*.2017.0040-8166.
26. Minami A, Nakanishi A, Ogura Y, Kitagishi Y, Matsuda S. Connection between tumor suppressor *BRCA 1* and *PTEN* in damaged DNA repair. *Frontiers in Oncology*. November 2014.318(4):1-8.
27. Richard SS, Suwahjo A, Liestyawan YA, editors. *Clinical Anatomy by Systems*. Washington DC : Wolters Kluwer Health, Inc; 2008.
28. Guyton, Arthur C, JhonE. *Buku Ajar Fisiologi Kedokteran*. 12th Ed. Jakarta:Saunders Elsevier. 2014. p. 1098-99.
29. Bates, Barbara. *Guide to Physical Examination and History Taking*. 8th ed. Washington DC: Lippincott Williams & Wilkins; 1998.
30. Paulsen F, Waschke J. *Sobotta Atlas Anatomi Manusia : Anatomi Umum dan Muskuloskeletal*. Penerjemah : Brahm U. Jakarta : EGC; 2013.
31. Faiz O, Moffat D. *Anatomy at a Glance*. Jakarta : Erlangga; 2004.
32. Price, Lucio Olivetti, editor. *Atlas of Imaging Anatomy*. New York : Springer; 2012.

33. Junqueira, Carneiro. Appendix. In Junqueira, Carneiro: Basic Histology. 11th ed. New York: McGraw-Hill; 2013.
34. Aman RA, Gondhowiardjo S, Rachman A, Suriadireja A, Syahrudin E, Tobing DL, et al. Ilmu Dasar Onkologi. 3rd ed. Jakarta: FK UI; 2013. p. 36-65.
35. Kader YA, El-Nahas T, Sakr A. Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens. Dovepress Journal Onco Targets and Therapy. 2013;6; 1073–1077.
36. Vantangoli MM, Madnick SJ, Huse SM, Weston P, Boekelheide K. MCF-7 Human Breast Cancer Cells Form Differentiated Microtissues in Scaffold-Free Hydrogels. PLoS ONE 10(8). : August 12, 2015.
37. Levenson AS, Jordan Craig. MCF-7: The First Hormone-responsive Breast Cancer Cell Line. *Cancer Research* 57. 3071-3078, August 1. 1997.
38. Lee AV, Osterreich S, Davidson NE. MCF-7 Cells—Changing the Course of Breast Cancer Research and Care for 45 Years. *Journal of the National Cancer Institute*. 2015 July 1; 107(7).
39. Comsa S, Anca M, Cimpean, Raica, Marius. The Story of MCF7 Breast Cancer Cell Line 40 Years of Experience in Research. *Anti Cancer Research* (35) 3147-3154. 2015
40. Abcam (2013). Guide to Human CD Antigen. Abcam discover more. www.abcam.com/CD - diakses pada 30 November 2017.
41. Gao ZW, Dong K, Zhang HZ. The Roles of CD73 in Cancer. *Biomed Research International*. 2014 July 14;2014; 1-9.
42. Zhi X, Wang Y, Yu J, Yu J, Zhang L, Yin L, *et al.* Potential Prognostic Biomarker CD73 Regulates Epidermal Growth Factor Receptor Expression in Human Breast Cancer. *IUMB Life*. 2012 November;64(11):911-920.
43. Wang X, Liu Y, Zhou K, Zhang G, Wang F, Ren J. Isolation and characterization of CD105+/CD90+ subpopulation in breast cancer MDA-MB-231 cell line. *Int J Clin Exp Pathol*. 2015;8(5):5105-5112.
44. Lobba ARM, Forni MF, Carreira ACO, Sogayar MC. Differential Expression of CD90 and CD14 Stem Cell Markers in Malignant Breast Cancer Cell Lines. *Cytometry Part A*. 2012 October 22;81A:1084-1091.
45. Ogle BM, Noubissi FK. Cancer Cell Fusion : Mechanism Slowly Unravel. *International Journal of Molecular Science*. 2016 September 21.17:1587;1-10
46. Pham VP, Vu NB, Pham VM, Truong NH, Pham TR, Dang LT, et al. Good Manufacturing Practice-Compliant Isolation And Culture Of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells. *Journal of Translational Medicine*. 2014, 12:56.
47. Petrucelli N, Daly MB, Pal T. *BRCA 1- and BRCA 2-Associated Hereditary Breast and Ovarian Cancer*. GeneReviews NCBI Bookshel. 2016 December 15. Diakses pada 31 Agustus 2017.

48. Homo sapiens Annotation Release 108, GRCh38.p7 (NCBI), diakses pada 31 Agustus 2017.
49. Lister Hill National Center for Biomedical Communications. U.S. National Library of Medicine. National Institutes of Health. Department of Health & Human Services BRCA2 gene BRCA2, DNA repair associated. September 26, 2017.
50. Kim S, Lee JW, Kim JH. Regulation of oncogenic transcription factor hTAFII68-TEC activity by human glyceraldehyde-3-phosphate dehydrogenase (GAPDH). *Biochemical Journal*.2007;404:197–206.
51. Barber RD, Harmer DW, Coleman RA, Clark BJ. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. *Physiol Genomics*.2005.21:389–395.
52. Thermo Fisher Scientific. TRIzol Reagent User Guide - Pub. no. MAN0001271 - Rev. A.0. Vol. 15596018, User Guide. USA; 2016. p. 1–6.
53. BIO-RAD. iScript™ cDNA Synthesis Kit. 2012. p. 4978. Available from: <http://www.bio-rad.com/webroot/web/pdf/lsr/literature/4106228.pdf>
54. Ma Y, Hao X, Zhang S, Zhang J. The In Vivo and In Vitro Effects of Human Umbilical Cord Mesenchymal Stem Cells on The Growth of Breast Cancer Cells. *Breast Cancer Res Treat*. 2012. 133 : p. 473-485
55. Maia AT, Antoniou AC, O'Reilly M, Samarajiwa S, Dunning M, Kartsonaki C, *et al*. Effect of BRCA 2 cis-regulation in normal breast ad cancer risk amongst BRCA 2 mutation carriers. *Breast Cancer Research*. 2012. 14 : p. 1-15
56. Bieche I, Nogues C, Lidereau R. Overexpression of BRCA2 Gene In Sporadic Breast Tumours. April 14, 1999. *Oncogene*. 18 :p. 5232-5238.
57. Adelman CR, Lau KM, Sabeti N, Long JP, Mok SC, Ho SM. Altered Expression of BRCA1, BRCA2, and a Newly Identified BRCA2 Exon 12 Deletion Variant in Malignant Human Ovarian, Prostate, and Breast Cancer Cell Lines. 2000. *Molecular Carcinogenesis* 28: p. 236-246
58. Tripathi MK, Misra S, Khedart SV, Hamilton N, Wilson CI, Sharan C. Regulation of BRCA 2 Gene Expression by The SLUG Repressor Protein in Human Breast Cancer Cells. *The Journal of Biological Chemistry*. February 14, 2005. 280:17. p. 17163-17171
59. Melzer C, Yang Y, Hass R. Interaction of MSC with tumor cells. *Cell Communications and Signalling*. 2016. 14:20. p. 1-12
60. Chen J, Crawford R, Chen C, Xiao Y. The Key Regulatory Roles of the PI3K/Akt Signaling Pathway in the Functionalities of Mesenchymal Stem Cells and Applications in Tissue Regeneration. *Tissue Engineering*. July 9, 2013. 19:6.p. 516-528
61. Ohta N, Ishiguro S, Kawabata A, Uppalapati D, Pyle M, Troyer D. Human Umbilical Cord Matrix Mesenchymal Stem Cells Suppress The Growth Of

- Breast Cancer By Expression Of Tumor Suppressor Genes. PLOS ONE. May 5, 2015. 10(5): p. 1-17.
62. American Type Culture Collection Breast Cancer. Stem Cell Culture Guide Tips And Techniques For Culturing Stem Cells. ATCC. 2015: Virginia. p : 4, 23.
 63. Dzobo K, Vogelsang M, Thomford NE, Dandara C, Kallmeyer K, Pepper MS. Wharton's Jelly-Derived Mesenchymal Stromal Cells and Fibroblast-Derived Extracellular Matrix Synergistically Activate Apoptosis in a p21-Dependent Mechanism in WHCO1 and MDA MB 231 Cancer Cells *In Vitro*. Stem Cells International. Decemcer 6, 2015. 2016.p: 1-17
 64. Mandel K, Yang Y, Schambach A, Glage S, Otte A, Hass R. Mesenchymal stem cells (MSC) directly interact with breast cancer cells and promote tumor cell growth *in vitro* and *in vivo*. Stem Cell and Development. 2013. p: 1-61
 65. Zhang C, Yang SJ, Wen Q, Zhong JF, Chen XL, Stucky A, *et al*. Human-derived normal mesenchymal stem/stromal cells in anti cancer therapies. Journal of Cancer. January 1, 2017. 8(1).p: 85-95
 66. Ayuzawa R, Doi C, Rachakatla RS, Pyle MM, Maurya DM, Troyer D. Naïve human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells *in vitro* and *in vivo*. Cancer Lett. July 18, 2009. 280(1).p: 1-14
 67. Bliss SA, Sinha G, Sandiford OA, Williams L, Engelberth DJ, Guiro K, *et al*. Mesenchymal stem cell-derived exosomes stimulates cycling quiescence and early breast cancer dormancy in bone marrow. American Association for Cancer Research. August 28, 2016.p.1-32

